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CObjectives: Transport of ions to generate epithelial rehydration (TI-
GER)-1 was a randomized trial conducted to evaluate the safety and
efficacy of denufosol versus placebo in patients with cystic fibrosis
withmild impairment in lung function. The trial met its primary end
point at 24 weeks, but a subsequent trial did not show a sustained
effect of denufosol at 48 weeks. By using the 48-week data, we char-
acterized resource use, direct medical costs, indirect costs, and util-
ity estimates. Methods: Data on medications, outpatient and emer-
ency visits, hospital admissions, tests, procedures, and home
ursing were captured on study case report forms. Sources for unit
osts included the Medicare Physician Fee Schedule, the Nationwide
npatient Sample, and the Red Book. Health utilities were derived
rom the Health Utilities Index Mark 2/3. We used multivariable re-
ression to evaluate the impact of baseline covariates on costs.
esults: Characteristics of the 352 participants at enrollment included O
c
c
rch In
al So
oi:10.1016/j.jval.2011.11.027ean age of 14.6 years, history of Pseudomonas aeruginosa colonization
n 45.2%, use of dornase alfa in 77.0%, and long-term use of inhaled
ntibiotics in 37.2%. Over 48 weeks, 22.4% of participants were hospi-
alized and, on average, participantsmissed 7.4 days of school or work.
ean total costs (excluding denufosol) were $39,673 (SD $26,842), of
hich 85% were attributable to medications. Female sex and P. aerugi-
osa colonization were independently associated with higher costs.
onclusions: Prospective economic data collection alongside a clin-
cal trial allows for robust estimates of cost of illness. The mean
nnual cost of care for patients with cystic fibrosis with mild impair-
ent in lung function exceeds $43,000 and is driven by medication
osts.
eywords: costs and cost analysis, cystic fibrosis, denufosol.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Cystic fibrosis (CF) is the most common autosomal genetic dis-
ease among white persons. It affects 1 in 2500 newborns and is
progressive and incurable. Advances in treatment have dramat-
ically increased life expectancy from less than 1 year in the
1930s to a median of 37 years today [1–3]. Despite treatment
advances, there is a lack of therapies that address the underly-
ing pathophysiology of disease rather than complications of the
disease. This underscores the importance of regimens to main-
tain health and the development of practice guidelines by the
Cystic Fibrosis Foundation on appropriate long-term use of
medications to preserve lung function [2,4–6].
Denufosol is a novel ion-channel regulator designed to tar-
get small airways and correct the ion-transport defect early in
disease progression to delay the onset and reduce the rate of
lung function loss [7]. A phase 3, multicenter, randomized, dou-
ble-blind, placebo-controlled trial (Transport of ions to generate
epithelial rehydration [TIGER]-1, Study 08-108) was recently
Trial Registration: clinicaltrials.gov Identifier: NCT00357279.
* Address correspondence to: Shelby D. Reed, Duke Clinical Resea
E-mail: shelby.reed@duke.edu.
098-3015/$36.00 – see front matter Copyright © 2012, Internation
ublished by Elsevier Inc.conducted to evaluate the safety and efficacy of denufosol in
patients aged 5 years and older with near normal to mildly im-
paired lung function, defined as baseline forced expiratory vol-
ume in the first second of expiration (FEV1) of 75% or more of the
predicted level, when added to the patient’s current therapeutic
regimen. Decline in FEV1 reflects progression of disease [8]. The
linical results of TIGER-1 demonstrated a statistically signifi-
ant benefit of denufosol on FEV1 at 24 weeks in a patient pop-
ulation with extensive background therapy [9]. In a subsequent
48-week randomized trial of denufosol (TIGER-2), however,
there were no sustained clinical benefits [10].
Clinical trial designs that incorporate routine clinical care
afford an efficient means of rigorously determining the total
cost of medical care when economic data are collected prospec-
tively as part of the trial [11]. A prospective economic evaluation
was integrated into TIGER-1 to allow for estimation of the cost of
illness over a 48-week period in persons with CF with normal to
mildly impaired lung function. Data on medical resource use,
health utilities, and CF disease–related time lost from school
and work were collected during the trial.
stitute, PO Box 17969, Durham, NC 27715, USA.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
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Study design
The clinical trial was conducted at 61 sites in theUnited States and
1 site in Canada. Eligible participants were aged 5 years or older,
had a confirmed diagnosis of CF, had mild impairment in lung
function with an FEV1 of 75% or more of the predicted level, and
ere clinically stable for 4 weeks before screening. Medications
sed to treat CF were allowed, and participants were instructed to
ontinue taking their medications consistently throughout the
tudy. The main exclusion criteria included abnormal renal or
iver function, history of liver or lung transplant, Burkholderia cepa-
ia colonization, change in medications within 28 days of screen-
ng, use of inhaled hypertonic saline within 2 weeks of screening,
nd use of oral corticosteroids exceeding 10mgonce daily or 20mg
very other day.
Participants were randomly assigned to active treatment with
enufosol or placebo. The double-blind treatment period contin-
ed for 24 weeks and was followed by a 24-week open-label safety
xtension period. Contact with participants occurred every 4
eeks during the 48-week trial and consisted of eight scheduled
linic visits (in addition to screening and post-trial visits) and six
elephone contacts to verify interval resource use,medication use,
nd adverse events. Additional details of the clinical trial protocol
ave been described elsewhere [9]. The institutional review board
f the Duke University Health System approved this study.
Health utilities
Patient-reported health preferences were measured at the ran-
domization visit and every 12 weeks during the trial with a Health
Utilities Index Mark 2/3 (HUI2/3) questionnaire and a visual ana-
logue scale (“feeling thermometer”) [12,13]. TheHUI2/3 is a 15-item
questionnaire designed to measure multiattribute health utility
scores representing the desirability of a given health state and has
been tested in adolescents with CF [13]. The questionnaire was
self-administered by trial participants 14 years and older. Parents
or caregivers of participants 13 years and younger completed the
instrument as proxies [14]. The HUI2/3 multiattribute utility scale
ranges from 0.36 to 1.00, where 0 represents death and 1.00 rep-
resents perfect health. Scores less than 0 represent health states
considered worse than death. The feeling thermometer rates
health states from the patient’s perspective on a vertical visual
analogue scale from 0 to 100, where 0 represents the worst imag-
inable health state and 100 represents the best imaginable health
state.
Medical resource use and missed school days/workdays
Data onmedical resource usewere recorded in the trial case report
form during each study visit or phone call through patient report
and supplemented with medical information available at the
study site. Resource use data included information on concomi-
tant medications, planned and unscheduled clinic visits to the
study site and primary care physician, inpatient and outpatient
tests and procedures, hospitalizations, emergency department
visits, and home nursing care. The number of days missed from
work or school by the participant because of CF-related illnesswas
also ascertained during each study visit and phone call.
Cost assignment
We valued costs from a societal perspective and included direct
medical costs and indirect costs attributable tomissed school days
and workdays. If 2008 cost estimates were unavailable, we up-
dated the values by using the consumer price index for medical
care [15]. vWe used average wholesale prices reported in the 2008 Red
Book [16] to assign medication costs. We assigned a daily cost to
each drug on the basis of dose, route, and frequency of adminis-
tration recorded in the case report form. We then multiplied the
daily cost by the estimated number of days of use from the date of
randomization through 48weeks. If a dosagewas not provided, we
assigned the most commonly used dose. We assumed that pan-
creatic enzymes reported taken “as needed”were taken four times
daily. We did not assign costs to the other 7.7% of drug records
with “as-needed” dosing.
Costs for outpatient visits, tests, and procedureswere based on
2008 Current Procedural Terminology codes and average reim-
bursement rates from the 2008 Medicare Physician Fee Schedule
[17]. Costs for emergency department visits and procedures were
also based on the Medicare Physician Fee Schedule. If the emer-
gency department visit did not result in hospitalization, the mar-
ginal cost of an emergency department visit was also included to
represent facility costs [18]. Home nursing visits were estimated
from the standardized, service-specific, per-visit payment rates
published by the US Centers for Medicare & Medicaid Services for
home health care in 2008 [19].
Hospitalization costs included physician fees for physician
rounds, physician fees for procedures, and hospital costs. Physi-
cian fees for rounding and inpatient procedures were assigned
corresponding Current Procedural Terminology codes and valued
by using the 2008 Medicare Physician Fee Schedule [17]. For the
hospital component, we developed a costing methodology to
ensure that inpatient costs would better represent costs in-
curred by patients with CF [20]. First, we assigned primary, sec-
ondary, and tertiary International Classification of Diseases, Ninth
Revision, Clinical Modification, codes based on the reasons for hos-
pitalization and inpatient procedures recorded in the trial. We
then identified hospitalizations of patients with CF in the 2001-
2005 Nationwide Inpatient Sample databases available from the
Agency for Healthcare Research and Quality [21]. We matched
hospitalizations in the trial to multiple Nationwide Inpatient
Sample records based on International Classification of Diseases,
Ninth Revision, Clinical Modification, diagnostic and surgical pro-
cedure codes. We estimated hospitalization costs in the trial by
multiplying the median daily cost based on matched Nationwide
Inpatient Sample discharges with each participant’s length of stay
in TIGER-1.
Indirect costs due to days lost from work were valued by using
the average hourly wage ($19.85) in the United States [22]. For pe-
diatric participants who missed a day of school, we assumed that
a parent missed a day of work.
Statistical analysis
Weestimated costs across several participant subgroups prespeci-
fied in an economic analysis plan, including subgroups defined by
age, long-term use of inhaled antibiotics, use of recombinant hu-
man deoxyribonuclease (dornase alfa or rhDNase), and Pseudomo-
nas aeruginosa infection. The use of pancreatic enzymes was not
considered as a subgroup because of near ubiquitous use. In a post
hoc analysis, we compared costs between treatment groups after
stratifying participants by bodymass index (BMI) below and above
a threshold indicating malnutrition (18.5 vs. 18.5 kg/m2) [23].
In multivariable analysis, we evaluated baseline determinants
f costs at 48 weeks by using a generalized linear model with a
amma error distribution and log link [24], which has been shown
o fitmedical cost data reasonablywell when extreme cost outliers
re not present. Among the independent variables, we treated age
s categorical (i.e., 5–7, 8–12, 13–17, 18 years). Treatment group
ssignment and the presence of two or more positive cultures for
. aeruginosa within 2 years of randomization were dichotomous
ariables. Baseline FEV and BMI were modeled as continuous1
ariables. We developed two separate models. One model applied
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variable, and the other model applied 48-week costs minus med-
ication costs.Weused SAS version 9.1 (SAS Institute Inc., Cary, NC)
for all analyses.
Results
From July 2006 through October 2007, 352 participants were en-
rolled in the study and randomly assigned to active or placebo
arms. Participant characteristics were balanced across treatment
groups. Table 1 shows the combined participant data; 51.4% were
emale and 94.6% were white, reflecting the genetics of the dis-
ase. In the year before enrollment, 18.8% of participants were
ospitalized at least once. More than four of five (82.1%) had pan-
reatic insufficiency, and 45.2% tested positive for P. aeruginosa on
two or more occasions during the previous 2 years. Nearly all par-
ticipants (92.0%) were receiving pancreatic enzymes at baseline,
77.0% were on dornase alfa, and 37.2% were on long-term inhaled
antibiotics, of which inhaled tobramycin accounted for 96.2%.
During the 24-week double-blind phase, 19 (10.7%) participants in
Table 1 – Baseline characteristics of the study
population.
Characteristic Overall
(n  352)
Age (y), mean (SD) 14.6 (9.0)
Female, n (%) 181 (51.4)
Race/ethnicity, n (%)
Asian 1 (0.3)
Black or African American 5 (1.4)
Hispanic or Latino 12 (3.4)
White 333 (94.6)
Other 1 (0.3)
Body mass index (kg/m2), mean (SD) 19.5 (3.7)
Hospitalization due to exacerbation of cystic
fibrosis lung disease in the past year, n (%)
66 (18.8)
Medical history, n (%)
Diabetes mellitus 23 (6.5)
Gastroesophageal reflux disease 109 (31.0)
Pancreatic insufficiency 289 (82.1)
Malabsorption 119 (33.8)
Reactive airway disease or asthma 123 (34.9)
Rhinitis 63 (17.9)
Sinusitis 158 (44.9)
Positive test result for Pseudomonas aeruginosa* 159 (45.2)
Baseline medication use
Pancreatic enzyme use 324 (92.0)
Bronchodilator use 283 (80.4)
Dornase alfa use 271 (77.0)
Macrolide use 139 (39.5)
Long-term inhaled antibiotic use 131 (37.2)
HUI2/3 utility score†
Mean (SD) 0.90 (0.14)
Median (interquartile range) 0.95 (0.88–1.00)
Feeling thermometer‡
Mean (SD) 88.3 (12.2)
Median (interquartile range) 90.0 (85.0–96.0)
HUI2/3, health utilities index mark 2 and mark 3.
* Positive test result for Pseudomonas aeruginosa two or more times
within 2 years of baseline via bronchoalveolar lavage, throat
swab, or sputum culture.
† Variable missing for 17 participants.
‡ Variable missing for 8 participants.the denufosol arm and 18 (10.3%) participants in the placebo armdiscontinued their participation in the trial (P  0.92). The most
commonly reported reason for discontinuationwas the time com-
mitment required with thrice-daily dosing in both treatment
groups. Discontinuation attributable to adverse events was low
(1%–3%) and similar between treatment groups.
Health preferences
Health preferences based on the HUI2/3 and feeling thermom-
eter were fairly high at baseline at 0.90 (SD 0.14) and 88.3 (SD
12.2) (Table 1). Neither measure of health preference changed
significantly over the 48-week follow-up period; mean change
was 0.01 (95% confidence interval0.013 to 0.031) for the HUI3/2
and 1.4 (95% confidence interval 0.47 to 3.33) for the feeling
thermometer.
Medical resource use and costs
During the 48-week study period, 79 of 352 participants (22.4%)
were hospitalized at least once (Table 2), for a total of 113 hospi-
talizations. Of these, 97 (85.8%) were related to CF. Among hospi-
talized participants, mean length of stay was 8.2 days (SD 6.9), and
14.5% of participants had at least one visit to the emergency de-
partment. Although fewer than one of four participants were hos-
pitalized, inpatient costs averaged $4367 per participant (Table 3).
Costs for emergency department visits averaged $103 per partici-
Table 2 – Medical resource use from baseline through 48
wk.
Resource Overall
(n  352)
Hospitalizations per patient, n (%)
0 273 (77.6)
1 53 (15.1)
2 19 (5.4)
3 6 (1.7)
4 1 (0.3)
Emergency department visits per patient, n (%)
0 301 (85.5)
1 39 (11.1)
2 9 (2.6)
3 3 (0.9)
Home nursing visits per patient, n (%)
0 329 (93.5)
1 5 (1.4)
2 5 (1.4)
3 7 (2.0)
4 6 (1.7)
Outpatient visits per patient, mean (SD)*
Routine visit to cystic fibrosis care center
physician
2.3 (2.8)
Unscheduled visit to cystic fibrosis care center
physician
0.8 (1.4)
Routine visit to primary care physician 0.9 (2.3)
Unscheduled visit to primary care physician 0.9 (1.5)
Total 5.0 (4.5)
Patients with one or more outpatient procedure,
n (%)
Bronchoscopy 9 (2.6)
Chest x-ray 86 (24.4)
Gastrointestinal x-ray 28 (7.9)
Peripherally inserted central catheter 18 (5.1)
Pulmonary function test 206 (58.5)
Sputum culture 189 (53.7)* Does not include trial-related visits.
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participants, including 32 visits by a single participant). On aver-
age, patients had 5.0 scheduled or unscheduled outpatient visits,
themajority ofwhichwerewith their CF care center physician, not
including study visits. The mean number of days missed from
school or work was 7.4, and associated indirect costs were an es-
timated $1180.
Costs were assigned to 39 different types of concomitant me-
diations and averaged $33,394 per participant. These medications
accounted formore than 86%of total directmedical costs (Table 3),
with dornase alfa accounting for 41.5%, inhaled tobramycin ac-
counting for 21.3%, and pancreatic enzymes (all brands combined)
accounting for 21.6% of the estimated cost for concomitant medi-
cations.
Subgroup analyses
Table 4 shows the results of the subgroup analyses. There were
substantial differences in mean costs across subgroups related to
sex (P  0.002), infection (P  0.001), and type of treatment
(P  0.001). For female participants, 48-week costs were approxi-
mately $44,800, compared with $34,900 for male participants. For
participants with documented P. aeruginosa infection within 2
years before the baseline visit, 48-week costs were approximately
$47,600, compared with $33,200 for participants without P. aerugi-
nosa infection. Among participants undergoing long-term treat-
ment with inhaled antibiotics at baseline, 48-week costs were ap-
proximately $58,800, compared with approximately $28,300 for
participants not taking inhaled antibiotics at baseline. Partici-
pants taking dornase alfa incurred mean costs of approximately
$46,000, compared with $18,600 for participants not taking dor-
nase alfa. Differences based on age and BMIwereminimal and not
Table 3 – Mean costs per patient from baseline through
48 wk.
Costs All participants
(n  352)
Inpatient hospitalizations
Mean (SD) 4367 (11,449)
Median (interquartile range) 0
Emergency department visits
Mean (SD) 103 (322)
Median (interquartile range) 0
Outpatient visits (nontrial)
Mean (SD) 593 (553)
Median (interquartile range) 458 (213–795)
Home nursing visits
Mean (SD) 36 (225)
Median (interquartile range) 0
Concomitant medications
Mean (SD) 33,394 (21,523)
Median (interquartile range) 30,970 (16,346–45,692)
Total direct medical costs
Mean (SD) 38,493 (26,275)
Median (interquartile range) 34,149 (21,893–52,649)
Indirect costs associated with
missed school days or
workdays*
Mean (SD) 1180 (2211)
Median (interquartile range) 398 (0–1310)
Direct plus indirect dosts
Mean (SD) 39,673 (26,842)
Median (interquartile range) 35,151 (22,742–54,236)
* For each day of school lost by a child younger than 18 y, we as-
sumed one parent lost a workday.statistically significant.Baseline predictors of costs
Consistent with the results of the subgroup analyses for medical
resource use, neither age nor BMI was independently associated
with higher or lower total costs during the 48-week period
(Table 5). Female participants, however, incurred costs that were
1.22 times higher than costs for male participants, and partici-
pants with a history of P. aeruginosa infection incurred costs that
were 1.41 times higher than costs for participants without P.
aeruginosa infection. Baseline FEV1 was not associated with higher
otal costs at 48 weeks. When we excluded outpatient medication
osts from the dependent variable, the effect of female sex was
tronger and history of P. aeruginosa infection also remained sig-
ificantly associated with costs. Costs were significantly lower
mong children aged 5 to 7 years, compared with adult partici-
ants. In addition, higher baseline FEV1 was significantly associ-
ated with lower costs.
Discussion
We considered total directmedical costs in personswith near nor-
mal or mildly impaired lung function and found that most costs
were associated with long-term health maintenance medication
use related to the treatment for CF. The period of analysis was the
48-week follow-up period in TIGER-1, throughout which data on
medical resource use, health preferences, and days missed from
school or work were collected prospectively. Study participants
continued their maintenance medications during the study, al-
lowing the opportunity for a rigorous accounting of the costs of
usual care for patients receiving treatment in CF care centers in
North America.
Approximately one in five participants were hospitalized or
evaluated in an emergency department during the study. Despite
the relatively low levels of acute care medical services provided to
Table 4 – Mean total costs of care by subgroup from
baseline through 48 wk.
Subgroup Cost, mean
(SD)
P*
Age (y)
19 35,432 (29,030) 0.17
5–18 40,745 (26,207)
Sex
Female 44,776 (28,517) 0.002
Male 34,853 (24,265)
Chronic use of inhaled antibiotics
Yes 58,799 (27,550) 0.001
No 28,336 (18,817)
Use of dornase alfa
Yes 45,958 (25,961) 0.001
No 18,648 (17,468)
Pseudomonas aeruginosa test result
Positive† 47,586 (30,040) 0.001
Negative 33,154 (21,909)
Body mass index (kg/m2)
18.5 40,604 (26,175) 0.59
18.5 38,852 (27,461)
* Pvalues are from a generalized linear model specified with a
gamma distribution and log link, and subgroup as only indepen-
dent variable.
† Positive test result for P. aeruginosa two ormore timeswithin 2 y of
baseline via bronchoalveolar lavage, throat swab, or sputumculture.
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281V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 7 7 – 2 8 3participants during the 48-week follow-up period, the mean an-
nual cost of illness for participants with CF with mild impairment
in lung function approached $43,000. This estimate is significantly
higher than estimates from previous studies. In a 1999 study by
Lieu et al. [25] from the perspective of a US health maintenance
rganization, the mean annual cost of treatment for mild CF lung
isease (i.e., FEV1  70%) was $6200 in 1996 dollars ($8100 in 2008
ollars), and the mean cost at all levels of disease severity was
13,300 ($17,400 in 2008 dollars) [26]. Given the small relative con-
ribution of indirect costs in our study, the difference in study
erspectives does not account for the large discrepancy. In a 2003
tudy by Baumann et al. [27] examining the cost of care in the
erman health system, estimated annual expenditures per pa-
ient were almost €24,000. This estimate included annual costs of
36,421 ($46,697 in 2008 dollars) for patients with P. aeruginosa and
10,861 ($13,925 in 2008 dollars) for patients without P. aeruginosa
nfection. In our study, annual costs were approximately $51,600
€40,250) for patients with P. aeruginosa infection and $35,900
(€28,000) for those without P. aeruginosa infection.
Outpatient medication costs in our study accounted for 86% of
total costs, considerably higher than in previous studies. In the
study by Lieu et al. [25], medication costs among patients with
mild lung disease constituted approximately one-third of total
costs. However, across severity levels, outpatient medications
have reportedly accounted for approximately half of total costs
[27,28]. Amore recent study fromFrance reported that 70%of costs
were attributable to long-termmedications (49%) and home intra-
venous antibiotics (21%) [29]. In our study, the dominance of med-
ication costs as a proportion of total costs is partly a function of the
relatively low costs for other medical resources. Nevertheless, our
estimate of medication costs exceeded $33,000 over 48 weeks.
Two main factors likely account for the higher costs in our
study. First, the findings reflect current practice patterns at med-
ical centers with expertise in CF. The study population consisted
of participants with mild impairment in lung function, and 77% of
participantswere treatedwith dornase alfa and 37% received long-
term treatment with inhaled antibiotics. In the study by Lieu et al.
[25], 36% of patients with mild lung disease received rhDNase and
20% received inhaled tobraymcin or intravenous aminoglycosides.
This finding may reflect the evolution of practice patterns over
time, including the timing of publication of Cystic Fibrosis Foun-
dation guidelines for the treatment of patients with pulmonary
disease in 2007 [2], which recommend the use of dornase alfa in
patients aged 6 years or older with CF with mild lung disease, or
variations in clinical practice across sites [30].
Second, we used average wholesale prices to estimate medica-
Table 5 – Multivariable analysis of the effects of baseline ch
Variable Total costs
Means ratio
(95% confidence interval)*
Intercept, $† 30,905 (22,870–41,764)
Female 1.22 (1.03–1.43)
Age group (vs age  18 y)
5 to 7 y 0.80 (0.50–1.27)
8 to 12 y 0.95 (0.67–1.36)
13 to 17 y 1.11 (0.85–1.45)
History of P. aeruginosa‡ 1.41 (1.20–1.66)
FEV1 at baseline 0.90 (0.76–1.06)
Body mass index at baseline 1.00 (0.97–1.03)
* Means ratios are exponentiated parameter estimates.
† Intercept terms represent mean costs for adults in the placebo gro
‡ Positive test result for P. aeruginosa 2 or more times within 2 yearstion costs. Average wholesale prices are published list prices; theyare often significantly higher than the true costs incurred by large
third-party payers such as private insurance companies andMed-
icaid [31]. The average estimated discounts in 2008 were 16% for
retail pharmacies and 23% for mail order pharmacies [32]. If we
had applied a discount of 20% to the estimatedmedication costs in
the analysis, annual estimated costs would have been over
$28,000. This estimate, however, might have underestimated total
medication costs, because we focused our cost assignment efforts
on high-cost and high-frequency medications and did not assign
costs to all medications reported in the trial (e.g., some “as
needed” medications such as pain medications were excluded if
no standard frequency could be assumed) or to inpatient medica-
tions. Also, we used several assumptions to estimate medication
costs with the available data. For example, some patients received
pancreatic enzymes “as needed.” For cost assignment, we as-
sumed these patients took pancreatic enzymes four times per day.
In multivariable analysis, sex and a history of infection with P.
aeruginosa at baselinewere significantly associatedwith costs. The
finding that female participants incurred higher costs was consis-
tent with the higher frequency of hospitalizations among female
participants in the study (P  0.05). An increased rate of hospital-
zation in female patients was noted previously in a cohort study
n which more intensive treatment in female patients was also
oted more generally [33]. P. aeruginosa infection within 2 years of
nrollment was significantly associated with higher total costs at
8 weeks. This finding may reflect long-term use of inhaled anti-
iotics in response to infection. However, even after we excluded
edication costs from the analysis, history of P. aeruginosa infec-
ion was associated with a higher cost of illness at 48 weeks. Con-
ruentwith this finding, participantswith a history of P. aeruginosa
nfection had a higher frequency of hospitalizations (P 0.01) and
ulmonary exacerbations (P  0.005) over 48 weeks than did par-
ticipants without P. aeruginosa infection. When we modeled total
costs, an age effect was not evident. The exclusion of medication
costs, however, allowed us to examine costs that were more
closely linked with changes in health status rather than with the
use of high-cost outpatient medications. After controlling for
baseline FEV1 and other factors, we found lower costs among the
oungest participants (aged 5–7 years) compared with adults in
he study. A review of hospitalizations and exacerbations showed
o significant differences in counts across age groups. It is possible
hat the observed difference in costs by age reflects the progres-
ive nature of the condition. Also, with the exclusion of medica-
ion costs,we found a significant association betweenhigher base-
ine FEV1 and lower 48-week costs, though this relationship was
not evident when we examined total costs. The lack of an associ-
cteristics on total costs.
Total costs minus medication costs
P value Means ratio
(95% confidence interval)*
P value
 .001 4117 (2002–8467)  .001
.02 1.55 (1.06–2.28) .02
.34 0.21 (0.07–0.65) .01
.79 0.57 (0.24–1.35) .20
.42 1.27 (0.66–2.45) .47
 .001 1.60 (1.10–2.32) .01
.21 0.60 (0.49–0.90) .01
.82 0.94 (0.89–1.01) .08
th no history of P. aeruginosa.
eline via bronchoalveolar lavage, throat swab, or sputum culture.ara
up wiation between FEV1 and total costs (including costs for outpatient
f
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s
r
[
[
[
[
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282 V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) 2 7 7 – 2 8 3medications) may represent the use of higher-cost medications
across patients with higher and lower FEV1.
When we examined total costs, the results differed somewhat
rom the study by Baumann et al. [27], in which total costs of CF
are did not vary by sex but higher costs were independently as-
ociated with older age and P. aeruginosa infection. Our finding
elated to P. aeruginosa was similar. Age was not associated with
total costs; however, when we excluded the costs of outpatient
medications, our findings regarding the effect of age were consis-
tent with those of Baumann et al. [27].
The primary strength of this study is its prospective design as
part of a randomized clinical trial. In addition, we developed and
applied a novel costing strategy for inpatient care in recognition of
the higher costs of hospitalization among patients with CF com-
paredwith patientswithout CF;we incorporated physician fees for
inpatient rounding and inpatient procedures, which are typically
missing in economic evaluations; andwe undertook great effort to
capture the large majority of costs for outpatient medications
throughout the study.We also included indirect costs to represent
time lost from work and school for patients and parents of chil-
dren with CF.
Limitations of the study include likely underestimation of costs
of outpatient visits. Because participants were contacted every 4
weeks either in clinical visits or by telephone, some routine out-
patient visits may have been replaced and/or urgent visits re-
duced. As a result, we were unable to capture the natural outpa-
tient experience at CF centers. However, these frequent points of
contact served to diminish recall bias and increase the reliability
of the reported data on resource use and days missed from school
or work. We were also unable to estimate costs of some classes of
medications prescribed to be taken only as needed, resulting in
some degree of underestimated costs. Study exclusion criteria
limited the sample to those not using hypertonic saline, but the
remainder of exclusion criteria were unlikely to affect the inclu-
sion of patients with mild lung disease. However, the relatively
homogeneous patient population, in terms of disease severity, al-
lowed us to better isolate other factors that were influential in cost
of care in patientswithmild lung disease. The drawback is that we
are unable to extrapolate results to patientswithmore severe lung
disease.We observed little change in utility values over the course
of the study. Given the starting clinical state of mild lung disease,
with a study span of less than a year, this is not unexpected. There
is no indication that this finding would differ from the general
population with CF withmild lung disease, unless participation in
the study itself resulted in improved health-related quality of life.
There are relatively few studies in the medical literature that
examine costs in patients with CF, and those that are available do
not represent contemporary practice patterns at specialty care
centers in the United States. Although our study focused on pa-
tients with mild impairment in lung function, the results reveal
that the annual cost of care for these individuals approached
$43,000 per year. The majority of the cost was related to medica-
tions for health maintenance in the outpatient setting. Relatively
little of the cost was related to inpatient stays or emergency de-
partment visits, perhaps a reflection of relativelymild lung disease
of study participants and their broad use of preventative and
maintenance health strategies. Additional burden of illness stud-
ies should be performed to characterize resource use and costs in
patients with more severe lung impairment to develop the evi-
dence base to evaluate the economic impact of existing and future
treatments that may slow the progression of disease.
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